טוען...
Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
Renal-cell carcinoma (RCC) affects over 330,000 new patients every year, of whom 1/3 present with metastatic RCC (mRCC) at diagnosis. Most mRCC patients treated with a first-line agent relapse within 1 year and need second-line therapy. The present study aims to compare overall survival (OS) between...
שמור ב:
| הוצא לאור ב: | PLoS One |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Public Library of Science
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4894561/ https://ncbi.nlm.nih.gov/pubmed/27271250 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0155389 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|